Moderna Partners with Nanexa on PharmaShell Drug Delivery Technology in $500M Deal
核心洞察
Moderna has signed a license and option agreement with Swedish pharmaceutical company Nanexa (搜索) to utilize their proprietary PharmaShell (搜索) drug delivery platform for up to five undisclosed compounds.
The deal includes a $3 million upfront payment and potential milestone payments of up to $500 million, plus tiered single-digit royalties on future product sales.
PharmaShell (搜索) technology uses atomic layer deposition to enable precise drug encapsulation with tailored release profiles over one to three months and room temperature storage capabilities.
Moderna has entered into a license and option agreement with Swedish pharmaceutical company Nanexa (搜索) to leverage their proprietary PharmaShell (搜索) drug delivery platform, potentially transforming how the mRNA pioneer delivers its therapeutic compounds. The deal structure includes an upfront payment of $3 million to Nanexa, with the potential for up to $500 million in development and commercial milestone payments, as well as a tiered single-digit royalty on future product sales.
Under the agreement, Moderna receives a license to use Nanexa (搜索)'s PharmaShell (搜索) technology with its first selected compound and holds options to obtain licenses for up to four additional compounds, covering the development of up to five undisclosed compounds in total. The collaboration aims to assess the potential of the PharmaShell technology to enhance the release profile of Moderna's selected compounds.
Advanced Drug Delivery Technology
The PharmaShell (搜索) technology, based on atomic layer deposition, enables precise encapsulation of active pharmaceutical ingredients. This process offers tailored release profiles over one to three months, terminal sterilization, improved stability and room temperature storage. These capabilities address key challenges in the delivery of advanced biologics (搜索).
Atomic layer deposition allows for customized drug release patterns that can be adjusted based on specific therapeutic needs. The technology's ability to maintain stability at room temperature eliminates the need for cold chain storage, a significant advantage for distribution and accessibility of medications.
Strategic Partnership Structure
If Moderna exercises its options for additional compounds following preclinical evaluation, each option would trigger a pre-negotiated license. This structure gives Moderna flexibility to evaluate the technology's effectiveness before committing to additional licenses. The milestone-based payment structure means Nanexa (搜索) will receive payments as specific development and commercial goals are achieved throughout the partnership.
"We are excited to partner with Moderna, a pioneer and leader in the field of mRNA medicines (搜索), to explore the potential of our PharmaShell (搜索) platform and to support the development of improved products for Moderna," said David Westberg, CEO of Nanexa (搜索). "This agreement underscores the versatility of PharmaShell and its potential to address key challenges in the delivery of advanced biologics (搜索)."
Implications for mRNA Therapeutics
For Moderna, the partnership provides access to innovative delivery technology that could enhance its mRNA-based therapeutics. The ability to extend drug release profiles and improve storage conditions could make Moderna's products more practical for wider distribution and patient use.
The partnership highlights growing pharmaceutical industry interest in advanced drug delivery systems that can improve patient outcomes and medication adherence. Long-acting injectables reduce the frequency of dosing required, which can significantly improve patient compliance with treatment regimens.
Global Distribution Advantages
The technology's room temperature storage capability could prove particularly valuable for global distribution of medications, especially in regions where maintaining cold chain logistics presents challenges. This feature could expand access to advanced therapeutics in underserved markets.
Nanexa (搜索)'s business model combines internal product development with strategic partnerships and technology licensing to leading pharmaceutical companies. The Uppsala-based company focuses on developing long-acting injectable drug delivery solutions using its proprietary PharmaShell (搜索) system, providing multiple pathways for growth and reducing dependence on any single revenue stream.